Christopher Pocock

6.0k citations
65 papers · 2.3k · 1 hit paper · h-index 24

Impact in

  • Genetics top 0.5%
    • Chronic Lymphocytic Leukemia Research
  • Hematology top 1%
    • Chronic Myeloid Leukemia Treatments
    • Acute Myeloid Leukemia Research

Papers in

Co-authors
David C. Linch (14 shared papers)Kirit M. Ardeshna (13 shared papers)Jane F. Apperley (13 shared papers)David Cunningham (13 shared papers)Andrew Jack (10 shared papers)John Davies (9 shared papers)John M. Goldman (10 shared papers)Wendi Qian (6 shared papers)
Journals
Blood (28 papers)British Journal of Haematology (11 papers)Journal of Clinical Oncology (6 papers)Hematological Oncology (2 papers)The Lancet Haematology (2 papers)
Partner nations
United KingdomAustraliaSwitzerland

In The Last Decade

Christopher Pocock

64 papers receiving 2.2k citations

Christopher Pocock's Hit Papers

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles 2013 · 379 citations
3790+4+8Years since publication100200300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2013 The Lancet

Peers

Christopher Pocock
Comparison fields: 5 of 67
  • Genetics 1.0k
  • Hematology 800
  • Pathology and Forensic Medicine 1.2k
  • Oncology 705
  • Rheumatology 347
Replace Ester Orlandi with:
Ester Orlandi Italy
Coralie Bélanger France
Piero Galieni Italy
Isabelle Plantier France
Lourdes Florensa Spain
Barbara Grant United States
Evelyne Callet‐Bauchu France
Hervé Ghesquières France
Vincent Delwail France
DC Linch United Kingdom
Christopher Pocock relative to Ester Orlandi Italy Ester Orlandi's profile →
Citations per field
00.5×2×2.7×
Ester Orlandi · 1×
Citations per year

Countries citing papers authored by Christopher Pocock

Since Specialization
Citations

This map shows the geographic impact of Christopher Pocock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Pocock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Pocock more than expected).

Fields of papers citing papers by Christopher Pocock

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Pocock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Pocock. The network helps show where Christopher Pocock may publish in the future.

Co-authors

The 25 scholars most cited alongside Christopher Pocock, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christopher Pocock Line = papers co-authored together Christopher Pocock links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 65 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
The Lancet ·David Cunningham, Eliza A. Hawkes, Andrew Jack, Wendi Qian, Paul Smith, Paul Mouncey, Christopher Pocock, Kirit M. Ardeshna, John Radford, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, Joanna Gambell, David C. Linch
Hit paper breakdown →		2013379
2
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
The Lancet Oncology ·Kirit M. Ardeshna, Wendi Qian, Paul Smith, Nivette Braganca, Lisa Lowry, Pip Patrick, June Warden, Lindsey Stevens, Christopher Pocock, Fiona Miall, David Cunningham, John Davies, Andrew Jack, Richard Stephens, Jan Walewski, Burhan Ferhanoğlu, Ken Bradstock, David C. Linch
2014265
3
Early detection of BCR-ABL transcripts by quantitative reverse transcriptase–polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia
Blood ·Eduardo Olavarría, Edward Kanfer, Richard Szydlo, Jaspal Kaeda, Katayoun Rezvani, Kate Cwynarski, Christopher Pocock, Francesco Dazzi, Charles Craddock, Jane F. Apperley, Nicholas C.P. Cross, John M. Goldman
2001128
4
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial
The Lancet Haematology ·(unknown), Fotios Polydoros, Jane F. Apperley, Dragana Milojković, Katherine A. Rothwell, Christopher Pocock, Jenny Byrne, Hugues de Lavallade, Wendy Osborne, Lisa Robinson, Stephen G. O’Brien, Lucy Read, Letizia Foroni, Mhairi Copland
2019119
5
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib
Blood ·David Marín, Corinne Hedgley, Richard E. Clark, Jane F. Apperley, Letizia Foroni, Dragana Milojković, Christopher Pocock, John M. Goldman, Stephen J. O’Brien
2012107
6
Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21).
PubMed ·Sarah Kulkarni, C Heath, Sally Parker, Andrew Chase, Syma Iqbal, Christopher Pocock, Jaspal Kaeda, Kate Cwynarski, John M. Goldman, Nicholas C.P. Cross
200099
7
Richter's transformation of chronic lymphocytic leukemia
Leukemia Research ·Patrick Thornton, C Bellas, Almudena Santón, Gunjan L. Shah, Christopher Pocock, Andrew Wotherspoon, Estella Matutes, Daniel Catovsky
200598
8
Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study
Journal of Clinical Oncology ·Peter Hillmen, John G. Gribben, George Follows, Donald Milligan, Hazem A. Sayala, Paul Moreton, David Oscier, Claire Dearden, Daniel B. Kennedy, Andrew R. Pettitt, Amit Nathwani, Abraham Varghese, D. Cohen, Andy C. Rawstron, Stephan Oertel, Christopher Pocock
201493
9
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial
The Lancet Haematology ·(unknown), Fotios Polydoros, Jane F. Apperley, Dragana Milojković, Christopher Pocock, Graeme Smith, Jenny Byrne, Hugues de Lavallade, Stephen G. O’Brien, Tony Coffey, Letizia Foroni, Mhairi Copland
201783
10
De Novo Treatment of Diffuse Large B-Cell Lymphoma With Rituximab, Cyclophosphamide, Vincristine, Gemcitabine, and Prednisolone in Patients With Cardiac Comorbidity: A United Kingdom National Cancer Research Institute Trial
Journal of Clinical Oncology ·Paul Fields, William Townsend, Andrew Webb, Nicholas Counsell, Christopher Pocock, Paul Smith, Andrew Jack, Nadjet El-Mehidi, Peter Johnson, John Radford, David C. Linch, David Cunnningham
201382
11
An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis
Blood ·Kirit M. Ardeshna, Wendi Qian, Paul Smith, June Warden, Lindsay Stevens, Christopher Pocock, Fiona Miall, David Cunningham, John Davies, Jan Walewski, A. Burhan Ferhanoglu, Ken Bradstock, David C. Linch
201074
12
Novel translocations that disrupt the platelet‐derived growth factor receptor β (PDGFRB) gene in BCR–ABL‐negative chronic myeloproliferative disorders
British Journal of Haematology ·E. Joanna Baxter, Shashikant Kulkarni, J.L. Vizmanos, R J Jaju, Giovanni Martinelli, Nicoletta Testoni, George S. Hughes, Zoryana Salamanchuk, Marı́a José Calasanz, Idoya Lahortiga, Christopher Pocock, Raymond Dang, Carrie Fidler, James S. Wainscoat, Jacqueline Boultwood, Nicholas C.P. Cross
200372
13
Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission
Blood ·Charles Craddock, Richard Szydlo, John P. Klein, Francesco Dazzi, Eduardo Olavarría, Frits van Rhee, Christopher Pocock, Kate Cwynarski, Jane F. Apperley, John M. Goldman
200057
14
Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial
Annals of Oncology ·Mary Gleeson, Nicholas Counsell, David Cunningham, Nicholas Chadwick, Anthony Lawrie, Eliza A. Hawkes, Andrew McMillan, Kirit M. Ardeshna, Andrew Jack, Peter Smith, Paul Mouncey, Christopher Pocock, John Radford, J. M. Davies, Deborah Turner, Anton Kruger, Peter Johnson, Joanna Gambell, David C. Linch
201754
15
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study
Haematologica ·Andrew M. Evens, Joseph M. Connors, Anas Younes, Stephen M. Ansell, Won Seog Kim, John Radford, Tatyana Feldman, Joseph M. Tuscano, Kerry J. Savage, Yasuhiro Oki, Andrew Grigg, Christopher Pocock, Monika Długosz‐Danecka, Keenan Fenton, Andres Forero‐Torres, Rachael Liu, Hina Jolin, Ashish Gautam, Andrea Gallamini
202137
16
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R‐CHOP) in the management of primary mediastinal B‐cell lymphoma: a subgroup analysis of the UK NCRI R‐CHOP 14 versus 21 trial
British Journal of Haematology ·Mary Gleeson, Eliza A. Hawkes, David Cunningham, Nick Chadwick, Nicholas Counsell, Anthony Lawrie, Andrew Jack, Paul Smith, Paul Mouncey, Christopher Pocock, Kirit M. Ardeshna, John Radford, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, Joanna Gambell, David C. Linch
201632
17
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia
British Journal of Haematology ·Peter Hillmen, D. Cohen, Kim Cocks, Andrew R. Pettitt, Hazem A. Sayala, Andy C. Rawstron, Daniel B. Kennedy, Chris Fegan, Don Milligan, John Radford, Jane Mercieca, Claire Dearden, Raphael Ezekwisili, Alexandra Smith, Julia Brown, Gillian Booth, Abraham Varghese, Christopher Pocock, (unknown)
201132
18
Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions
Bone Marrow Transplantation ·Kate Cwynarski, Rebecca Goulding, Christopher Pocock, Francesco Dazzi, Charles Craddock, Jaspal Kaeda, Eduardo Olavarría, Ed Kanfer, Jane F. Apperley, Mark Lawler, JM Goldman
200129
19
A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma
Journal of Clinical Oncology ·David Cunningham, Peter Smith, Paul Mouncey, W. Qian, Christopher Pocock, Kirit M. Ardeshna, John Radford, J. M. Davies, Andrew McMillan, David C. Linch
200927
20
Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study
Blood ·Peter Hillmen, John G. Gribben, George Follows, Donald Milligan, Hazem A. Sayala, Paul Moreton, David Oscier, Claire Dearden, Daniel B. Kennedy, Andrew R. Pettitt, Amit Nathwani, D. Cohen, Andy C. Rawstron, Christopher Pocock
201027

About Christopher Pocock

Christopher Pocock is a scholar working on Pathology and Forensic Medicine, Hematology, Genetics, Oncology and Pulmonary and Respiratory Medicine, having authored 65 papers that have together received 2.3k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (29 papers), Chronic Lymphocytic Leukemia Research (26 papers), Chronic Myeloid Leukemia Treatments (18 papers), Acute Myeloid Leukemia Research (11 papers), Hematopoietic Stem Cell Transplantation (7 papers), Eosinophilic Disorders and Syndromes (7 papers), Viral-associated cancers and disorders (6 papers) and CNS Lymphoma Diagnosis and Treatment (6 papers). The work is most often cited by research in Genetics (1.0k citations), Hematology (800 citations), Pathology and Forensic Medicine (1.2k citations), Oncology (705 citations) and Rheumatology (347 citations). Christopher Pocock has collaborated with scholars based in United Kingdom, Australia and Switzerland. Frequent co-authors include David C. Linch, Kirit M. Ardeshna, Jane F. Apperley, David Cunningham, Andrew Jack, John Davies, John M. Goldman, Wendi Qian, John Radford and Peter Johnson. Their work appears in journals such as Blood, British Journal of Haematology, Journal of Clinical Oncology, Hematological Oncology and The Lancet Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ester OrlandiBreakdown of academic impact, for papers by Coralie BélangerBreakdown of academic impact, for papers by Piero GalieniBreakdown of academic impact, for papers by Isabelle PlantierBreakdown of academic impact, for papers by Lourdes FlorensaBreakdown of academic impact, for papers by Barbara GrantBreakdown of academic impact, for papers by Evelyne Callet‐BauchuBreakdown of academic impact, for papers by Hervé GhesquièresBreakdown of academic impact, for papers by Vincent DelwailBreakdown of academic impact, for papers by DC Linch